In the past decade, the discovery and characterization of broadly neutralizing antibodies 23 (bnAbs) to the highly conserved stem region of influenza hemagglutinin (HA) have provided 24 valuable insights for development of a universal influenza vaccine. However, the genetic barrier 25 for resistance to stem bnAbs has not been thoroughly evaluated. Here, we performed a series 26 of deep mutational scanning experiments to probe for resistance mutations. We found that the 27 genetic barrier to resistance to stem bnAbs is generally very low for the H3 subtype but 28 substantially higher for the H1 subtype. Several resistance mutations in H3 cannot be 29 neutralized by stem bnAbs at the highest concentration tested, do not reduce in vitro viral fitness 30 and in vivo pathogenicity, and are often present in circulating strains as minor variants. Thus,
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38
The major surface antigen of influenza virus, the hemagglutinin (HA), is composed of a highly 39 variable globular head domain that houses the receptor binding site and a conserved stem 40 domain that is responsible for membrane fusion (1). All of the major antigenic sites on HA are 41 located on the HA globular head (2-5), which is immunodominant over the stem (6) . However, 42 most antibodies to the globular head domain are strain-specific. In contrast, although harder to 43 elicit during natural infection or vaccination, many HA stem antibodies have impressive cross-44 reactive breadth (7, 8) . The isolation, characterization and structure determination of broadly 45 neutralizing antibodies (bnAbs) to the HA stem over the past decade have provided tremendous 46 insights into antiviral and vaccine development against influenza virus (9), including immunogen 47 design towards a universal influenza vaccine (10) (11) (12) . Several stem bnAbs are also currently in 48 clinical trials as therapeutics (13) . Stem bnAbs have also provided templates for design of small 49 proteins, peptides and small molecules against influenza virus (14-18). Therefore, while 50 influenza virus remains a major global health concern, stem bnAbs open up multiple promising 51 avenues to tackle this challenging problem.
53
However, emergence of resistance mutations can be a major obstacle for antiviral and vaccine 54 development. Several studies have reported difficulty in selecting strong resistance mutations to 55 stem bnAbs even after extensive passaging of the viruses (19-21), or through deep mutational 56 scanning (22), which is a comprehensive and unbiased approach (23). Nonetheless, strong 57 resistance mutations have been reported in other studies through virus passaging (20, 24, 25) .
58
It is unclear then why some studies were able to identify strong resistance mutations while 59 others could not. Here we systematically compare how readily resistance can emerge to stem 60 bnAbs in H3 and H1 HAs, and find that there are major differences between the subtypes.
62
Deep mutational scanning of the major HA stem epitope 63 4 CR9114 (26) and FI6v3 (27) are two bnAbs that bind the HA stem and have exceptional 64 neutralization breadth. They are in fact two of the known bnAbs with the greatest breadth 65 against influenza viruses. Both FI6v3 and CR9114 neutralize group 1 and 2 influenza A viruses 66 (26, 27) , and CR9114 further cross-reacts with influenza B HA (26). Deep mutational scanning 67 (23), which combines saturation mutagenesis and next-generation sequencing, has previously 68 been applied to study how HA mutations affect influenza viral fitness (28-30), and to identify 69 viral mutants that are resistant to anti-HA antibodies (31). Here, we employed deep mutational 70 scanning of the HA stem on influenza virus to search for resistance mutations to CR9114 and 71 FI6v3. We focused on eight HA2 residues in the HA stem of H3N2 A/Hong Kong/1/1968 72 (H3/HK68): namely Q42, I45, D46, Q47, I48, N49, L52, and T111 ( Fig. 1 , A to C). All except 73 T111 are located on HA2 helix A, which is a common target for stem bnAbs. Residues 42, 45, 74 46, 48, 49, 52 interact with CR9114 and FI6v3, whereas residue 47 only interacts with FI6v3 75 (Fig. 1, D and E) . The completely buried T111 was also selected because its mutation in H5 HA 76 enabled escape from CR6261 (24), which binds a similar epitope to CR9114 (26, 32).
78
We quantified the in vitro fitness of 147 out of 152 possible single viral mutants and 6,234 out of 79 10,108 possible double viral mutants across the eight residues of interest in H3/HK68 HA2 80 under five different conditions: no antibody, 2 µg/mL CR9114 IgG, 10 µg/mL CR9114 IgG, 0.3 81 µg/mL FI6v3 IgG, and 2.5 µg/mL FI6v3 IgG ( fig. S1 ). In the absence of antibody, many viral 82 mutants have a relative fitness [proxy for replication fitness (30)], similar to wild type (WT), 83 which was set as 1 (Fig. 2, A and B) , and indicate that the HA stem region can tolerate many 84 mutations.
86
We further quantified the relative resistance of each viral mutant by normalizing their relative and E). In addition, the double mutants also showed high relative resistance if one mutation 91 exhibited high relative resistance even if the other did not ( fig. S3 ). Overall, these results 92 demonstrate the prevalence of H3/HK68 resistance mutations to stem bnAbs and mutations 93 with cross-resistance to both CR9114 and FI6v3, even though these bnAbs are encoded by 94 different germline genes and have very different angles of approach to the HA (8). 103 against mutants I45Y/S/N/F/W were all >100 and ≥20 µg mL -1 , respectively, compared to 3.1 104 and 0.2 µg mL -1 for WT. This validation experiment substantiates our finding that strong 105 resistance mutations are prevalent in H3/HK68.
107
Natural occurrence of resistance mutations 108 Next, we explored whether these resistance mutations were found in naturally circulating strains 109 While most strong resistance mutations have not yet been observed in naturally circulating 110 strains, it is important to note that a few could be identified at low frequency in natural human 111 H3N2 isolates (33), including I45T, I45M and N49D ( Fig. 4A ). I45T is also observed in human 112 H3N2 isolates sequenced without any passaging ( fig. S4A ), implying that its presence was not 113 due to a passaging artifact (34). Moreover, the strong cross-resistance mutation I45F was found 114 in all human H2N2 viruses that circulated from 1957 to 1968 ( Fig. 4B, fig. S4B ), while almost all 115 6 avian H2N2 viruses have Ile45 (Fig. 4C ), and explains why it is more difficult for human H2N2 116 viruses to be bound or neutralized by some stem bnAbs compared to other subtypes (24, 26, 117 35). Thus, these findings suggest that some resistance mutations to stem bnAbs already occur 118 in circulating strains.
120
In vivo pathogenicity and escape of resistance mutations
121
We further tested the in vivo viral pathogenicity of HA2 mutants I45T, I45M, and I45F, which are 122 of relevance to circulating strains (see above). The weight loss profiles in mice after infection by 123 HA2 mutant and WT viruses were comparable ( fig. S5 ), indicating that these resistance 124 mutations do not reduce in vivo pathogenicity. We further demonstrated that I45T, I45M, and 125 I45F were able to escape in vivo prophylactic protection. While mice infected with WT were 126 completely protected by CR9114 IgG at all tested doses (1, 4, and 10 mg kg -1 ), mutants I45T, 127 I45M, and I45F were lethal even at the highest dose of CR9114 IgG (Fig. 4 , D to G).
129
Resistance mutations decrease affinity to bnAbs 130 To dissect the resistance mechanism, we tested the binding of H3/HK68 I45T, I45M, and I45F 131 recombinant HAs to CR9114 and FI6v3, and also to another stem bnAb 27F3 (35), which 132 utilizes the same V H 1-69 germline as CR9114 and similarily neutralizes group 1 and 2 influenza 133 A viruses. The binding (K d ) of CR9114 Fab, CR9114 IgG, 27F3 Fab, 27F3 IgG, and FI6v3 IgG 134 was all diminished against the HA mutants compared to WT (Table 1 and fig. S6 ), and was 135 particularly dramatic with the I45F mutant, where binding was undetectable to CR9114 Fab and 136 IgG, and 27F3 Fab and IgG. In contrast, the binding of these stem Fabs and IgGs to N49T, 137 which did not exhibit any resistance against CR9114 and FI6v3 (Fig. 2C, Fig. 3A ), are 138 comparable to the WT (Table 1) . As a control, we also tested binding of bnAb S139/1 that 139 targets the receptor-binding site far from the stem epitope (36, 37) . S139/1 IgG affinities against 7 those HA mutants (K d = 1.8 nM to 3.1 nM) were similar to WT (K d = 2.1 nM). Thus, virus 141 resistance to stem bnAbs correlated with a decrease in binding affinity to the mutant HAs.
143
To understand the structural basis of the resistance, we determined crystal structures of HAs 144 with HA2 mutations I45T, I45M, and I45F to 2.1 to 2.5 Å resolutions (table S1 and fig. S7A ).
145
Compared to WT (Ile45), the shorter side chain of I45T would create a void when CR9114 is fig. S7B ), but CR9114 is still able to bind the 148 I45M mutant, albeit with much lower affinity than WT (Table 1) . The I45F mutant, however, 149 makes a more severe clash with CR9114 and no binding was detected (Table 1, previous studies (38, 39) . We also analyzed the previously published dataset on H1/WSN 178 against FI6v3 (22).
180
To compare H1/SI06, H1/Mich15, H1/WSN and H3/Perth09 to H3/HK68, we computed the 181 relative resistance of mutations at HA2 residues 42, 45, 46, 47, 48, 49, 52, and 111 (Fig. 5 , A to 182 E). Similar to H3/HK68, resistance mutations are highly prevalent in H3/Perth09 (Fig. 5C ).
183
Conversely, resistance mutations were rare in H1/SI06 (Fig. 5A ), H1/Mich15 (Fig. 5B) , and 184 H1/WSN (Fig. 5, D and E) . We further calculated the fraction surviving (22) 188 were all very small, similar to previous observations of H1/WSN against FI6v3 (Fig. 5F, fig. 189 S10). In stark contrast, many mutants of H3/Perth09 were identified with a large fraction 190 surviving value (Fig. 5F) . Consistent with the relative resistance profile of H3/HK68 (Fig. 2C) , a 191 number of H3/Perth09 mutants with a large fraction surviving value were again at HA2 residues 192 9 42 and 45 ( Fig. 5F and fig. S11A ). Moreover, mutations at HA2 residue 53, which were not 193 examined in H3/HK68 (Fig. 2) , had high fraction surviving in H3/Perth09 against FI6v3 ( fig. S11, 
194
A and B). In H3 HA, mutation of HA2 residue 53 would abolish a hydrogen bond to the 195 complementarity-determining region (CDR) H3 of FI6v3 ( fig. S11B ). Together, these results
196
suggest that the prevalence of resistance mutations to stem bnAbs is a general phenomenon for 197 the H3 subtype, but not the H1 subtype.
199
Subtype-specific differences in the HA stem
200
We next aimed to elucidate the mechanism that underlies the lower genetic barrier to resistance 201 to stem bnAbs in H3 HA as compared to H1 HA. Many mutations at HA2 residue 45 have a high 202 fitness cost in H1/SI06 ( fig. S9A ), which can increase the genetic barrier to resistance. However, 203 most mutations at HA2 residue 45 have no fitness cost in H1/Mich15. In addition, the mutational 204 fitness profiles of H1/SI06 and H1/Mich15 (fig. S9, A and B) show that many mutations can be 205 tolerated in the HA stem, similar to H3/HK68 ( Fig. 2A, fig. S9 , C to F). Thus, the difference in 206 genetic barrier to resistance to stem bnAbs between H1 and H3 subtypes cannot be fully 207 explained by their ability to tolerate mutations (i.e. fitness cost of mutations).
209
We therefore further compared the structures of CR9114 in complex with H3 HA and in complex 210 with H5 HA (Fig. 5G) (26) . Since the structure of CR9114 with H1 HA is not available, CR9114 211 with H5 HA was used instead, as it also belongs to group 1 HAs and is therefore more similar to 212 H1 than to H3 HA (group 2). Structural comparison indicates that CR9114 packs tighter to the 213 helix A of H3 HA than to H5 HA. Specifically, there is ~1 Å difference in the position of the Cα of 214 HA2 Ile45. Subsequently, a bulkier substitution at HA2 Ile45, such as I45M, would create a 215 larger disruption of the CR9114-HA binding interface in the context of H3 subtype. Thus, subtle 216 differences in the binding of bnAbs to different HA subtypes may lead to differences in how 217 antibodies are affected by mutations in or near the epitope.
219
Similar observations can be made for FI6v3. The orientation of Tyr100c on CDR H3 of FI6v3 220 differs when binding to H1 or H3 HAs (Fig. 5H) (27) . The position of HA2 Ile45 also differs 221 between H1 and H3 HAs when FI6v3 is bound. As a result, Tyr100c of FI6v3 packs tighter to 222 HA2 Ile45 of H3 than to H1 HA. Thus, a bulkier substitution at HA2 Ile45 will disrupt binding 223 between FI6v3 and H3 HA to a greater extent than FI6v3 to H1 HA. Therefore, the low genetic 224 barrier to resistance to stem bnAbs in the H3 subtype can be at least partly attributed to both 225 high mutational tolerance in the HA stem and subtype-specific structural features. While a 226 number of subtype-specific structural features are known in the stem region (40), how these 227 structural differences influence the genetic barriers for resistance to stem bnAbs remains to be 228 addressed in future studies.
230
Ramifications for escape from a universal vaccine or therapeutic stem bnAbs 231
Prior studies of influenza bnAbs have not considered whether different subtypes might have 232 different abilities to generate resistance mutations against bnAbs. A major finding here is that 233 H3 HA has a much lower genetic barrier to resistance to two of the broadest bnAbs, CR9114 234 and FI6v3, as compared to H1 HA. This observation is consistent with the literature, where 235 strong resistance to other human HA stem antibodies have been reported in H3 subtype (20, 236 25, 41) versus none (20) to weak resistance (21, 22) in the H1 subtype. Therefore, it may be 237 easier for stem bnAbs to maintain suppression of the H1 subtype than the H3 subtype.
239
Since the HA stem is immunosubdominant to the globular head domain, immunological 240 pressure on the HA stem may not have been sufficient to impact the evolution of circulating 241 influenza strains (42). However, several stem bnAbs are currently in clinical trials for therapeutic 242 purposes (13) and a number of recently developed influenza vaccine immunogens have 243 focused on targeting the HA stem (8, 9) . If stem bnAbs begin to be distributed on a global scale, 244 11 the immunological pressure on the HA stem will certainly surge to a level not previously seen.
245
Our findings here indicate that resistance mutations could emerge, at least in H3 subtype.
247
Although resistance mutations to stem bnAbs are still rare in currently circulating influenza 248 strains (Fig. 4A) , it is important to evaluate the potential impact of such mutations since many 249 vaccine strategies aim to elicit anti-stem antibodies. In fact, we were not able to overcome some 250 key resistance mutations (I45T, I45M, and I45F) by in vitro evolution of CR9114 ( fig. S12 ).
251
Nonetheless, the best strategy to prevent or overcome such resistance may involve delivery or 252 elicitation of a combination of antibodies with different resistance profiles. In addition, it remains 253 to be explored whether stem bnAbs exist or can be generated that are difficult to escape from 254 the H3 subtype. The discovery and characterization of bnAbs with different escape profiles will 255 therefore continue to be key to broaden our arsenal against influenza virus. For example, 256 human H2N2 virus, which carries a Phe at HA2 residue 45, often has low reactivity with stem 257 bnAbs (24, 26, 27, 35, 43) , although a very few can have high potency against human H2N2 (44) (45) (46) . Future studies on anti-stem responses against human H2N2 and emerging viruses, 259 such as H5N1 and H7N9, may provide further insights into how to overcome potential 260 resistance when immune pressure is transferred to the HA stem. 261 glycoprotein of influenza virus at 3 Å resolution. Nature 289, 366-373 (1981) . 
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